CASI Pharmaceuticals Inc. (CASIF) vs GT Biopharma, Inc. (GTBP)
CASI Pharmaceuticals Inc. and GT Biopharma, Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and GT Biopharma, Inc. are of similar size ($12.4M and $12.3M). CASI Pharmaceuticals Inc. grew revenue faster over the last twelve months: −27.4% against −76.2%. GT Biopharma, Inc. has the higher net margin (0.00% vs −232.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, CASI Pharmaceuticals Inc. leads on 8 and GT Biopharma, Inc. on 8.
Valuation
Profitability
| Metric | CASIF | GTBP | Biotechnology median |
|---|---|---|---|
| Gross margin | 48.65% | 41.67% | 65.16% |
| Operating margin | (206.87%) | 0.00% | 0.00% |
| Net margin | (232.03%) | 0.00% | 0.00% |
| Free cash flow margin | (432.54%) | 0.00% | 0.00% |
| Return on equity | 0.00% | 102.03% | (57.72%) |
| Return on assets | 0.00% | (176.27%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack